Aktis Oncology’s (AKTS) “Outperform” Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Aktis Oncology (NASDAQ:AKTS) in a report released on Friday morning,Benzinga reports. Wedbush currently has a $35.00 target price on the technology company’s stock.

Several other analysts have also recently issued reports on the company. JPMorgan Chase & Co. increased their target price on Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 14th. Raymond James Financial initiated coverage on Aktis Oncology in a report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price target on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of Aktis Oncology in a research note on Friday, September 18th. Oppenheimer initiated coverage on shares of Aktis Oncology in a report on Wednesday, September 9th. They set an “outperform” rating and a $40.00 price objective for the company. Finally, BMO Capital Markets initiated coverage on shares of Aktis Oncology in a research report on Tuesday, August 18th. They set an “outperform” rating and a $37.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.62.

Aktis Oncology Stock Performance

Shares of Aktis Oncology stock opened at $18.52 on Friday. The company has a market capitalization of $995.45 million and a P/E ratio of -22.59. The company has a fifty day moving average of $23.45 and a 200 day moving average of $22.16. Aktis Oncology has a fifty-two week low of $14.72 and a fifty-two week high of $34.19.

Aktis Oncology (NASDAQ:AKTS) last posted its quarterly earnings results on Thursday, August 13th. The technology company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). The business had revenue of $3.38 million during the quarter, compared to analyst estimates of $2.70 million. Analysts forecast that Aktis Oncology will post -1.85 EPS for the current year.

Insider Activity at Aktis Oncology

In related news, Director Ken Herrmann sold 4,856 shares of the stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $24.56, for a total transaction of $119,263.36. Following the completion of the transaction, the director directly owned 3,506 shares of the company’s stock, valued at approximately $86,107.36. This represents a 58.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Tidal Investments LLC bought a new position in Aktis Oncology during the second quarter valued at $1,839,000. Squarepoint Ops LLC bought a new stake in shares of Aktis Oncology in the 2nd quarter worth about $1,237,000. Readystate Asset Management LP purchased a new stake in shares of Aktis Oncology during the 2nd quarter valued at about $967,000. AXQ Capital LP bought a new position in shares of Aktis Oncology in the 2nd quarter valued at about $226,000. Finally, Susquehanna International Group LLP bought a new position in shares of Aktis Oncology in the 2nd quarter valued at about $278,000. 28.84% of the stock is owned by hedge funds and other institutional investors.

About Aktis Oncology

Aktis Oncology, Inc is a clinical-stage biopharmaceutical company developing targeted alpha therapies for the treatment of cancer. Its research is focused on creating therapies designed to selectively deliver alpha-particle radiation to tumor cells while limiting exposure to surrounding healthy tissue.

The company’s platform uses proprietary tumor-targeting molecules, including engineered miniproteins, to bind specific targets found on cancer cells and transport radioactive payloads to tumors.